China Oncology: an increasing burden and growth opportunity
With 50 % of global gastric, hepatic, and esophageal cancer cases and high lung cancer incidence, China Oncology market is a unique and challenging opportunity for multinational and local Biopharma.
BlueJet Consulting can help portfolio, launch and go-to-market strategy.
